blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3681489

EP3681489 - METHODS FOR TREATING DEPRESSION AND MAJOR DEPRESIVE DISORDER [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  19.06.2020
Database last updated on 13.07.2024
FormerThe international publication has been made
Status updated on  16.03.2019
Most recent event   Tooltip22.09.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Carmel Haifa University Economic Corporation Ltd.
Eshkol Tower, Haifa University
Mount Carmel
31905 Haifa / IL
[2020/30]
Inventor(s)01 / ROZENBLUM, Yaacov
12 Te'ashur Street
3095223 Zikhron Ya'akov / IL
02 / TAHA, Elham
2496300
Kabul / IL
03 / ADAIKKAN, Chinnakkaruppan
9 Kidder Avenue
Somerville Massachusetts 02144 / US
 [2020/30]
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[2020/30]
Application number, filing date18853562.906.09.2018
[2020/30]
WO2018IL51010
Priority number, dateUS201762556440P10.09.2017         Original published format: US 201762556440 P
[2020/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019049148
Date:14.03.2019
Language:EN
[2019/11]
Type: A1 Application with search report 
No.:EP3681489
Date:22.07.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 14.03.2019 takes the place of the publication of the European patent application.
[2020/30]
Search report(s)International search report - published on:IL14.03.2019
(Supplementary) European search report - dispatched on:EP23.04.2021
ClassificationIPC:A61K31/135, A61K38/17, A61P25/24, G01N33/68
[2021/21]
CPC:
A61P25/24 (EP,US); A61K38/005 (US); A61K31/135 (EP,US);
A61K38/162 (US); A61K38/17 (EP); G01N33/6896 (EP);
G01N2333/4727 (EP); G01N2500/00 (EP); G01N2800/304 (EP) (-)
Former IPC [2020/30]A61K31/135, A61P25/24, A61K38/10
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/30]
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON DEPRESSION UND SCHWERER DEPRESSION[2020/30]
English:METHODS FOR TREATING DEPRESSION AND MAJOR DEPRESIVE DISORDER[2020/30]
French:MÉTHODE DE TRAITEMENT DE LA DÉPRESSION ET DU TROUBLE DÉPRESSIF MAJEUR[2020/30]
Entry into regional phase17.03.2020National basic fee paid 
17.03.2020Search fee paid 
17.03.2020Designation fee(s) paid 
17.03.2020Examination fee paid 
Examination procedure17.03.2020Examination requested  [2020/30]
22.11.2021Amendment by applicant (claims and/or description)
Fees paidRenewal fee
02.09.2020Renewal fee patent year 03
02.09.2021Renewal fee patent year 04
23.08.2022Renewal fee patent year 05
22.09.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2009042906  (UNIV COLORADO [US], et al) [Y] 1-15* example 2 *;
 [X]US2010304391  (LOMBARD JAY L [US]) [X] 1,2 * paragraphs [0026] - [0027] - [0179] *;
 [XY]WO2015018375  (SHANGHAI INST BIOL SCIENCES [CN]) [X] 1-7,11-14 * abstract * [Y] 8-10,15;
 [XY]US2017247374  (LEVY DANIEL EMIL [US], et al) [X] 1-7,11-14 * paragraphs [0005] , [0168]; claim 16 * [Y] 8-10,15;
 [X]  - LI KUN ET AL, "[beta]CaMKII in Lateral Habenula Mediates Core Symptoms of Depression", SCIENCE, US, vol. 341, no. 6149, doi:10.1126/science.1240729, ISSN 0036-8075, (20130829), pages 1016 - 1020, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932364/pdf/nihms532664.pdf, (20210412), XP055794245 [X] 1-6,11-14 * pages 3-4 *

DOI:   http://dx.doi.org/10.1126/science.1240729
 [Y]  - AHMED MOHAMMAD EJAZ ET AL, "Beneficial Effects of a CaMKII[alpha] Inhibitor TatCN21 Peptide in Global Cerebral Ischemia", JOURNAL OF MOLECULAR NEUROSCIENCE, BIRKHAEUSER, CAMBRIDGE, MA, US, vol. 61, no. 1, doi:10.1007/S12031-016-0830-8, ISSN 0895-8696, (20160907), pages 42 - 51, (20160907), XP036128997 [Y] 1-15 * pages 45-46 *

DOI:   http://dx.doi.org/10.1007/s12031-016-0830-8
International search[XY]  - Steven j. Coultrap, Et Al, "Autonomous CaMKII Mediates Both LTP and LTD Using a Mechanism for Differential Substrate Site Selection", Cell Reports, US, (20140201), vol. 6, no. 3, doi:10.1016/j.celrep.2014.01.005, ISSN 2211-1247, pages 431 - 437, XP055677830 [X] 1 [Y] 2-19, 21

DOI:   http://dx.doi.org/10.1016/j.celrep.2014.01.005
 [XY]  - A J Robison et al, "Fluoxetine Epigenetically Alters the CaMKIIα Promoter in Nucleus Accumbens to Regulate ΔFosB Binding and Antidepressant Effects", NEUROPSYCHOPHARMACOLOGY, US, (20140401), vol. 39, no. 5, doi:10.1038/npp.2013.319, ISSN 0893-133X, pages 1178 - 1186, XP055677840 [X] 1 [Y] 2-19, 21

DOI:   http://dx.doi.org/10.1038/npp.2013.319
 [Y]  - Ying Xu, Et Al, "Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, Cambridge, (20160401), vol. 19, no. 4, doi:10.1093/ijnp/pyv124, ISSN 1461-1457, pages 1 - 15, XP055677845 [Y] 2-14, 21

DOI:   http://dx.doi.org/10.1093/ijnp/pyv124
 [Y]  - Rasmussen Keith G et al, "Serial infusions of low-dose ketamine for major depression", JOURNAL OF PSYCHOPHARMACOLOGY, GB, (20130501), vol. 27, no. 5, doi:10.1177/0269881113478283, ISSN 0269-8811, pages 444 - 450, XP009171072 [Y] 2-14, 21

DOI:   http://dx.doi.org/10.1177/0269881113478283
 [Y]  - Rong-Jian Liu, Et Al, "GSK-3 Inhibition Potentiates the Synaptogenic and Antidepressant-Like Effects of Subthreshold Doses of Ketamine", NEUROPSYCHOPHARMACOLOGY, US, (20131001), vol. 38, no. 11, doi:10.1038/npp.2013.128, ISSN 0893-133X, pages 2268 - 2277, XP055677848 [Y] 2-19, 21

DOI:   http://dx.doi.org/10.1038/npp.2013.128
 [Y]  - Chun Yang, Et Al, "Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test", UPSALA JOURNAL OF MEDICAL SCIENCES, SE, (20130301), vol. 118, no. 1, doi:10.3109/03009734.2012.724118, ISSN 0300-9734, pages 3 - 8, XP055677851 [Y] 15-17

DOI:   http://dx.doi.org/10.3109/03009734.2012.724118
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.